ice Committee. Cancer Chemotherapy Guidelines and Recommendations for Practice. Pittsburgh, PA: Oncology Nursing Society; 1999:32-41.
Recommendations for the safe handling of parenteral antineoplastic drugs. Washington, DC: Division of Safety, Clinical Center Pharmacy Department and Cancer Nursing Services, National Institutes of Health and Human Services, 1992, US Dept of Health and Human Services, Public Health Service publication NIH 92-2621.
AMA Council on Scientific Affairs. Guidelines for handling parenteral antineoplastics. JAMA. 1985;253:1590-1591.
National Study Commission on Cytotoxic Exposure. Recommendations for handling cytotoxic agents. 1987. Available from Louis P. Jeffrey, Chairman, National Study Commission on Cytotoxic Exposure. Massachusetts College of Pharmacy and Allied Health Sciences, 179 Longwood Avenue, Boston, MA 02115.
Clinical Oncological Society of Australia. Guidelines and recommendations for safe handling of antineoplastic agents. Med J Australia. 1983;1:426-428.
Jones RB, Frank R, Mass T. Safe handling of chemotherapeutic agents: a report from the Mount Sinai Medical Center. CA-A Cancer J for Clin. 1983;33:258-263.
American Society of Hospital Pharmacists. ASHP technical assistance bulletin on handling cytotoxic and hazardous drugs. Am J Hosp Pharm. 1990;47:1033-1049.
Controlling Occupational Exposure to Hazardous Drugs. (OSHA Work-Practice Guidelines.) Am J Health-Syst Pharm. 1996;53:1669-1685.
Preventing Occupational Exposures to Antineoplastic and Other Hazardous Drugs in Health Care Settings. NIOSH Alert 2004-165.
GlaxoSmithKline
Research Triangle Park, NC 27709
ARRANON is a registered trademark of GlaxoSmithKline.
©2006, GlaxoSmithKline. All rights reserved.
July 2006
RL-2297
PHARMACIST-DETACH HERE AND GIVE INSTRUCTIONS TO PATIENT
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ __ _ _ _ _ _ _ _
PATIENT INFORMATION LEAFLET
ARRANON® (AIR-ra-non)
Nelarabine Injection
Read the Patient Information that comes with ARRANON before you or your child start treatment with ARRANON. Read the information you get each time before each treatment with ARRANON. There may be new information. This information does not take the place of talking with the doctor about your or your child’s medical condition or treatment. Talk to your or your child’s doctor, if you have any questions.
What is the most important information I should know about ARRANON?
ARRANON may cause serious nervous system problems including:
-
extreme sleepiness
-
seizures
-
coma
-
numbness and tingling in the hands, fingers, feet, or toes (peripheral neuropathy)
-
weakness and paralysis
Call the doctor right away if you or your child has the following symptoms:
-
seizures
-
numbness and tingling in the hands, fingers, feet, or toes
-
problems with fine motor skills such as buttoning clothes
-
unsteadiness while walking
-
increased tripping while walking
-
weakness when getting out of a chair or walking up stairs
These symptoms may not go away even when treatment with ARRANON is stopped.
What is ARRANON?
ARRANON is an anti-cancer medicine used to treat adults and children who have:
-
T-cell acute lymphoblastic leukemia
-
T-cell lym
